Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of HSK42360-Na in Patients With BRAF V600 Mutation Locally Advanced or Metastatic Solid Tumors
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 阶段1
联系人和位置
学习联系方式
学习联系方式
- 姓名:lin shen
- 电话号码:0086-10-88196561
- 邮箱:doctorshenlin@sina.cn
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100142
- 招聘中
- Beijing Cancer Hospital
-
接触:
- lin shen
- 电话号码:0086-10-88196561
- 邮箱:doctorshenlin@sina.cn
-
Beijing、Beijing Municipality、中国、100070
- 招聘中
- Beijing Tiantan Hospital,Capital Medical University
-
接触:
- WenBin Li
- 电话号码:15301377998
- 邮箱:neure55@126.com
-
-
参与标准
资格标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age ≥ 18 years#Male and female patients, at time of signing informed consent form (ICF).
- ECOG performance status 0-1, or KPS (Karnofsky Performance Status) Score≥70.
- Life expectancy ≥ 3 months.
- Patients with locally advanced or metastatic solid tumors confirmed by histology or cytology, who have failed standard treatment (disease progression after treatment or intolerable treatment); patients who have previously received BRAF and/or MEK inhibitor therapy are allowed to be included in this study.
- Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360-Na.
- Patients will provide blood or tumor sample according to their own willingness.
- Measurable or non-measurable disease by RECIST 1.1 or RANO criteria.
- Brain metastasis patients with inactive CNS lesions; Original intracranial tumor patient with inactive CNS lesions, or patients treated with ≤4mg/day corticosteroid and without convulsion for ≥2 weeks.
- Adequate hematologic, hepatic, and renal function.
- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose.
Exclusion Criteria:
- malignant tumor within 2 years, with the exception of cutaneous squamous cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma, or other tumors with low malignancy.
- Uncontrollable pleural effusion, ascites, or pericardial effusion per protocol.
Treatment with any of the following:
Prior treatment with anti-tumor drug within 4 weeks or approximately 5 × t1/2 prior to the first dose of HSK42360-Na, whichever is shorter; Prior treatment with nitrosourea or mitomycin C within 6 weeks prior to the first dose of HSK42360-Na; Prior treatment with palliative radiotherapy or anti-tumor herbs within 2 weeks prior to the first dose of HSK42360-Na; Prior treatment with radiotherapy, electric field therapy, or other anti-tumor therapies within 4 weeks prior to the first dose of HSK42360-Na.
- Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia, dermal toxicity, and other toxicity considering no safety risks by investigator.
- Any disease which would preclude drug absorption, metabolism or pharmacokinetics, e.g. active peptic ulcer or chronic gastroesophageal reflux disease.
- Patients who have clinically significant or uncontrolled cardiac disease, include: QTc interval ≥ 450(male)/470(female) msec; any clinically significant arrhythmia; left ventricular ejection fraction < 50%; myocardial infarction, unstable angina, or class III/IV cardiac failure by the NYHA that occurred within 6 months prior to the first dose of HSK42360-Na.
- Any thromboembolic events within 6 months prior to the first dose of HSK42360-Na; any familial or acquired thrombophilia.
- Uncontrolled hypertension (systolic pressure≥160mmHg, or diastolic pressure≥100mmHg), diabetes (fasting blood-glucose≥10mmol/L), seizures, chronic obstructive pulmonary disease (COPD), interstitial pneumonia, pulmonary interstitial fibrosis, Parkinson's disease, active bleeding, or systemic active infection.
- Any unstable systemic disease, e.g. severe metabolic disease: liver cirrhosis, renal failure, or uremia.
- Treatment with inhibitors/inducers for CYP3A4, or substrates of CYP3A4, CYP2C9, CYP2C8, OATP1B1, OATP1B3, OAT1, OAT3, P-gp or BCRP within 14 days or approximately 5 × t1/2 prior to the first dose of HSK42360-Na, whichever is shorter.
- Patient with cognitive dysfunction, or history of mental illness, other uncontrolled comorbidities, alcohol dependence, hormone dependence or drug abuse.
- Autologous transplantation surgery within 3 months prior to the first dose of HSK42360-Na; Allogeneic transplantation, or stem-cell Transplant surgery within 6 months prior to the first dose of HSK42360-Na; Major surgery or significant traumatic injury occurring within 4 weeks prior to the first dose of HSK42360-Na.
- Patient with a history of immunodeficiency, including HIV positive, or other acquired/congenital immunodeficiency diseases.
- Any disease of the eyes > CTCAE v5.0 Grade 1.
- Patient with active hepatitis B or hepatitis C.
- Patient with active syphilis infection.
- Allergic to any HSK42360-Na active constituent or ingredients.
- Participate in other clinical trials within 4 weeks prior to the first dose of HSK42360-Na.
- Positive pregnancy test, or breastfeeding.
- Any other circumstances that would, in the investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Phase Ia: HSK42360-Na as monotherapy
Phase 1a (Part A): dose escalation of HSK42360-Na as monotherapy at various dose levels
|
Oral administration
|
|
实验性的:Phase Ib: HSK42360-Na as monotherapy
Phase 1b: dose expansion for HSK40118 as monotherapy at a dose determined during Phase 1a
|
Oral administration
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
MTD
大体时间:最长约 52 个月
|
MTD 测定:剂量限制毒性 (DLT) 率
|
最长约 52 个月
|
|
DLT
大体时间:最长约 52 个月
|
第 0 周期和第 1 周期的剂量限制性毒性 (DLT) 发生率
|
最长约 52 个月
|
|
AEs
大体时间:Up to approximately 52 months
|
Rate and severity of adverse events of HSK42360-Na as monotherapy
|
Up to approximately 52 months
|
|
RP2D
大体时间:Up to approximately 52 months
|
The RP2D is determined based on multiple parameters
|
Up to approximately 52 months
|
|
ECOG Performance Status Scale
大体时间:Up to approximately 52 months
|
Change of the grade as a part of HSK43260 safety data.
Scores range from 0 to 5, with lower scores indicating better patient performance status.
|
Up to approximately 52 months
|
|
Karnofsky Performance Scale, KPS
大体时间:Up to approximately 52 months
|
Change of the grade as a part of HSK43260 safety data.
Scores range from 0 to 100, with higher scores indicating better patient performance status.
|
Up to approximately 52 months
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
疾病控制率(DCR)
大体时间:最长约 52 个月
|
DCR,定义为根据 RECIST 1.1 获得 CR、PR 或疾病稳定 (SD) 最佳缓解的患者比例
|
最长约 52 个月
|
|
响应持续时间 (DOR)
大体时间:最长约 52 个月
|
DOR,定义为从首次记录的完全缓解 (CR) 或部分缓解 (PR) 缓解到首次记录的进展性疾病或任何原因导致的死亡(以先发生者为准)的日期的时间
|
最长约 52 个月
|
|
总体缓解率 (ORR)
大体时间:最长约 52 个月
|
ORR,定义为根据 RECIST 1.1/RANO 获得确认 CR 或 PR 最佳缓解的患者比例
|
最长约 52 个月
|
|
无进展生存期 (PFS)
大体时间:最长约 52 个月
|
PFS,定义为任何原因导致的死亡或死亡时间,以先发生者为准
|
最长约 52 个月
|
|
Overall survival (OS)
大体时间:Up to approximately 52 months
|
OS, defined as the time from the first dose of HSK42360-Na until the date of death due to any cause
|
Up to approximately 52 months
|
|
Area under the curve (AUC) of HSK42360-Na
大体时间:Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days)
|
Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days)
|
|
|
maximum plasma concentration (Cmax) of HSK42360-Na
大体时间:Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days)
|
Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days)
|
|
|
half-life (t1/2) of HSK42360-Na
大体时间:Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days)
|
Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days)
|
|
|
Tmax(Time to maximum plasma concentration) of HSK42360-Na
大体时间:Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days)
|
Circle 0 (single-dose circle, 3 days) and circle 1 (multiple-dose circle, 21days)
|
其他结果措施
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
循环肿瘤 DNA (ctDNA)
大体时间:最长约 52 个月
|
评估治疗诱导的 MAPK 通路生物标志物的调节
|
最长约 52 个月
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他研究编号
其他研究编号
- HSK42360-Na-T1-101
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.